Barclays maintains Ultragenyx Pharmaceutical at Overweight, lowers price target to $32 from $35
Barclays kept its Overweight rating on Ultragenyx Pharmaceutical but reduced its price target from $35 to $32, citing an 8.6% decrease. The new target suggests an 86.5% upside from the Nov 4 close of $17.16. Recent analyst price targets for the company range from $17 to $34.
How this was made

The 30-second read
Why it matters
A lower price target may trigger short‑term selling and could influence other analysts to follow suit.
Market read
Analyst target revision is the primary new information, offering modest trading relevance.
What to watch
Potential pipeline milestones or partnership announcements not covered in the article.
Background
Barclays' analyst note updates ULTX's valuation based on recent data, but the article provides no additional company developments.
Market effects
May affect other rare‑disease biotech stocks as analysts reassess sector valuations.
Limited to US biotech market.
Low
Counterpoint
The target cut could be overly cautious if upcoming trial data exceeds expectations.
Key entities
- AnalystBarclays
Equity research firm issuing the target revision.
- CompanyUltragenyx Pharmaceutical
Biotech firm focused on rare diseases.

